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Objective: Common diseases often have an inflammatory component reflected by associated markers such as serum C-reactive
protein (CRP) levels. Circulating CRP levels have also been associated with adipose tissue as well as with specific CRP genotypes.
We examined the interaction between measures of body mass index (BMI), waist circumference and fat percent (total fat
measured by bioimpedance) with genotypes of the CRP gene in the determination of CRP levels.
Methods: The first 2296 participants (mean age 76±6 years, 42% men) in the Age, Gene/Environment Susceptibility-Reykjavik
Study, a multidisciplinary epidemiological study to determine risk factors in aging, were genotyped for 10 single nucleotide
polymorphisms (SNPs) in the CRP gene. General linear models with age and terms for interaction of CRP genotypes with BMI,
waist circumference and percent fat were used to evaluate the association of genotypes to CRP levels (high-sensitivity method,
range 0–10 mg l1) in men and women separately.
Results: We focused on the SNP rs1205 that represents the allele that captures the strongest effects of the gene on CRP levels.
Carriers of the rs1205 G allele had significantly higher CRP levels than noncarriers in a dose-dependent manner. Compared to
the AA genotype, the slope of the increase in CRP with increasing BMI (P¼ 0.045) and waist circumference (P¼0.014) was
different for the G allele carriers and of similar magnitude in both men and women. The rs1205 interactions were not significant
for fat mass percent, suggesting a possible association with fat localization.
Conclusions: This study further illuminates the known association between measures of adiposity and CRP levels and is shown to
be dependent on variation in the rs1205 SNP of the CRP gene. The correlated increase in CRP levels with adiposity is accentuated
by presence of the G allele.
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Introduction
C-reactive protein (CRP) has been implicated as a marker of
systemic low-grade inflammation. Elevated circulating CRP
levels have been found in Alzheimer’s disease1,2 as well as in
common diseases such as cardiovascular disease (CVD)3–7
and type 2 diabetes mellitus (T2DM),8–10 suggesting that
these common diseases could have an inflammatory
connection.
CRP is primarily produced in the liver and synthesis is
regulated by other inflammatory cytokines such as interleukin
6 (IL-6).11–13 However, in obese individuals an important part
of the circulating CRP is produced in adipose tissue.14
Circulating CRP levels have been shown to be associated with
adipose tissue, and total body fat has been shown to be a
predictor of CRP levels. There is evidence for a different degree
of participation of the different adipose tissue compartments.15
Visceral adipose tissue has been shown to be a promoter of low-
grade CRP inflammation16,17 and can produce higher levels of
Il-6 than subcutaneous fat.18
Circulating CRP levels have been associated to some extent
with common variation in several genes19 but primarily CRP
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gene variation.19–21 This is reviewed in detail in an article by
Hage et al.,6 Kathiresan et al.22 constructed a linkage dis-
equilibrium (LD) map and found associations between indivi-
dual single nucleotide polymorphisms (SNPs) and CRP levels,
and one common triallelic CRP SNP that is modestly associated
with serum CRP levels. In addition, genetic variation associated
with CRP levels has been associated with coronary heart
disease21 or acute myocardial infarction.23 Lange et al.4 found
genetic association with CRP levels as well as CVD risk in the
elderly. However, there are a number of other studies that have
not been able to identify an association between CRP genotype
and the risk of CVD.24–26
The two major factors consistently influencing circulating
CRP levels are adipose tissue14–17 and the CRP gene itself.4,20–22
The aim of this study was to analyze the effects of CRP gene
polymorphisms on CRP levels in a cohort of older Icelanders
and determine if there is interaction between various measures
of adiposity and genotypes of the CRP gene in the determina-
tion of CRP levels.
Materials and methods
Study population
This sample is drawn from the first 2296 participants who were
enrolled in the Age, Gene/Environment Susceptibility (AGES)-
Reykjavik Study (mean age 76±6 years, 42% men). The AGES-
Reykjavik Study is a follow-up of the original Reykjavik Study,27
started in 1967 by the Icelandic Heart Association where all
inhabitants in the Reykjavik area, born between 1907 and
1935, were invited to participate, consisting of approximately
30000 individuals. AGES-Reykjavik is an epidemiological study
that focuses on four biological systems: vascular, neurocogni-
tive, musculoskeletal and body composition, which was
initiated in 2002 to investigate the contribution of genetic
and environmental risk factors and their interactions to
disorders of importance in old age. All participants signed an
informed consent form and the AGES-Reykjavik Study was
approved by the Icelandic National Bioethics Committee (VSN:
00-063), the Data Protection Authority and the institutional
review board of the National Institute on Aging. A more
detailed description of the AGES-Reykjavik study and
collection of data can be found elsewhere.28
Measurements
Blood pressure and anthropometric data including body
mass index (BMI) and waist circumference were collected
using standardized protocols.28 Individuals missing either
BMI or waist circumference measurements were excluded. A
Xitron HYDRA ECF/ICF, Model 4200, was used to measure
body composition with the bioelectrical impedance analysis
(BIA) to assess the composition of the total body. From these
BIA data, and additional variables such as age, gender and
body weight, the fat-free mass (FFM, in kg) of the body can
be estimated using prediction equations. Fat mass (FM, in kg)
can subsequently be calculated as body weight minus FFM.
High-sensitivity CRP was measured on a Hitachi 912, using
reagents from Roche Diagnostics and following the manufac-
turer’s instructions. Both within- and between-assay quality
control procedures were used and the coefficient of variation of
the method was 1.3–3.4%, respectively, through the period of
data collection. The assay could detect a minimal CRP
concentration of 0.1mg l1 and values below this level were
classified as undetectable. All participants in this study had
detectable CRP levels. A total of 145 persons with CRP levels
greater than 10mg l1 were excluded, as this high level of CRP
was considered to be due to the acute-phase response.
Fasting blood glucose, total cholesterol, high-density lipo-
protein (HDL) cholesterol and triglycerides were also measured
on a Hitachi 912 using reagents from Roche Diagnostics and
following the manufacturer’s instructions. Insulin was mea-
sured by an electrochemiluminescence immunoassay on a
Roche Elecsys 2010 instrument, using two monoclonal anti-
bodies and a sandwich principle. The method was standardized
using the first IRP WHO Reference Standard 66/304 (NIBSC).
Trained interviewers administered a health history question-
naire to obtain smoking history information (ever smokers).
The 10 SNPs in the CRP gene, rs2808630, rs2808631,
rs1205, rs1130864, rs1800947, rs1417938, rs3093062,
rs2027471, rs1341665 and rs2808634, were analyzed using
an Illumina GoldenGate assay (Illumina, San Diego, USA).
These SNPs were chosen as candidate SNPs to cover the CRP
gene including 10 kb surrounding the gene, in a larger group
of candidate genes as part of a cardiovascular panel. SNPs
were chosen as those that effectively tag the region based on
HapMap CEU genotypes, as well as being compatible with
Illumina GoldenGate technology. The SNPs were overlap-
ping with SNPs that have been used in other studies.21,22
Two SNPs (rs2808631 and rs3093062) were nonpolymorphic
in the samples examined and DNA samples from seven
individuals failed to be genotyped.
Statistical analyses
C-reactive protein was log-transformed and analyzed with
general linear regression models by sex and adjusted for age.
rs1205 was entered as a categorical variable with genotype
AA as the reference. Association with body fat measurements
was estimated by genotype-specific slopes by introducing
interaction terms. The significance of the interaction was
found by testing the hypothesis of equal slopes between
genotypes based on an F-test from the general linear model.
The level of significance was set at 0.05. We analyzed the
data using SAS/STAT software, version 9.1.
Results
Table 1 shows the general characteristics of the study cohort
and the difference between sexes. Women have higher fat
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mass percent, cholesterol, HDL and triglycerides than men.
Men have higher waist circumference, glucose and insulin
levels than women. There is an increase in serum CRP levels
with increasing BMI (r¼0.26, r2¼0.07, Po0.0001), waist
circumference (r¼0.21, r2¼0.05, Po0.0001) and fat mass
percent (r¼ 0.21, r2¼0.05, Po0.0001) in both sexes. These
factors account for 5–7% of the variance of CRP levels,
shown by r2.
The observed allele frequencies for all SNPs were consistent
with expectation under Hardy–Weinberg equilibrium
(P40.01). LD values (r2) are shown in Table 2a. The following
individual SNPs, rs1205, rs1130864, rs1800947, rs1417938,
rs2027471 and rs1341665, were significantly associated with
CRP levels, when tested individually after adjusting for age
and sex (Table 2b). There was a dose-dependent decrease in
CRP levels with the minor allele of rs1205 in men (Table 3).
Looking at the LD values in Table 2a, there are three distinct
groups of tagging SNPs that can be observed: (1) rs1800947
does not capture the effect of other SNPs, (2) rs1205 captures
the effects of rs2027471 and rs1341665 and (3) rs1130864
captures the effect of rs1417938 on CRP levels. Haplotypes
derived from these SNPs were tested and no clear evidence for
stronger association to CRP levels with any one haplotype as
compared to individual SNPs was observed.
All SNPs were tested to see if the effects of anthropometric
factors on CRP levels vary across genotypes. A statistically
Table 1 General characteristics
Characteristics Men Women Difference of effect between sexes
n Mean, s.d. (95% CI) n Mean, s.d. (95% CI) % (95% CI) Pa
Age (years) 904 76.3 (5.6) 1226 76.2 (5.8)
SBP (mm Hg) 904 142.4 (20.4) 1226 141.6 (21.2) None
Anthropometric measures
BMI (kg m2) 904 26.6 (3.6) 1226 26.9 (4.8) None
Waist circumference (cm) 904 101.8 (10.3) 1226 99.7 (12.9) 2.5 (1.5, 3.6) o0.0001
Fat (%) 757 32.8 (6.5) 923 42.4 (5.6) 31.1 (28.9, 33.3) o0.0001
Blood measurements
CRP (mg l1)b 904 1.73 (0.75, 3.98) 1226 1.86 (0.80, 4.29) 6.8 (0.6, 14.8) 0.0713
Glucose (mM) 904 6.0 (1.2) 1226 5.7 (1.0) 2.8 (1.8, 3.8) o0.0001c
Cholesterol (mM) 904 5.3 (1.0) 1226 6.1 (1.1) 16.2 (14.3, 8.1) o0.0001
HDL (mM) 904 1.4 (0.4) 1226 1.7 (0.4) 22.7 (20.0, 25.5) o0.0001
Triglycerides (mM)b 904 1.07 (0.68, 1.69) 1226 1.14 (0.73, 1.78) 6.2 (2.2, 10.4) 0.0022
Insulin (mU l1)b 904 8.7 (8.4, 9.1) 1226 7.8 (7.6, 8.1) 7.6 (1.9, 13.5) 0.0283c
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; SBP, systolic blood pressure. The difference between sexes is shown by
the percent difference in effect size. aAge adjusted. bGeometric means. cAdjusted for T2DM (type 2 diabetes mellitus).
Table 2 (a) LD of SNPs (30-50 order) tested in the CRP gene. (b) Correlation of genotypes of individual SNPs in the CRP gene with CRP levels
LD(r2) rs2808630 rs1205 rs1130864 rs1800947 rs1417938 rs2027471 rs1341665 rs2808634
(a)
rs2808630 1 0.197995 0.187928 0.028194 0.191442 0.205566 0.205915 0.975775
rs1205 1 0.222652 0.143046 0.223100 0.967392 0.965347 0.191156
rs1130864 1 0.031875 0.994888 0.228120 0.226536 0.202133
rs1800947 1 0.032499 0.141475 0.141725 0.027718
rs1417938 1 0.228684 0.227288 0.204529
rs2027471 1 0.998964 0.198381
rs1341665 1 0.198719
rs2808634 1
SNP MAF ba P-value
(b)
rs2808630 0.31 0.037 0.19
rs1205 0.31 0.116 3.1 105
rs1130864 0.32 0.110 7.7 105
rs1800947 0.06 0.235 5.2 106
rs1417938 0.32 0.115 3.7 105
rs2027471 0.32 0.103 1.9 104
rs1341665 0.32 0.101 2.8 104
rs2808634 0.30 0.044 0.12
Abbreviations: CRP, C-reactive protein; LD, linkage disequilibrium; SNP, single nucleotide polymorphism. ab values are relative to the major allele.
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significant effect was found with SNPs rs1205, rs2027471 and
rs1341665. As discussed above the two latter SNPs,
rs2027471 and rs1341665, are in complete LD with rs1205
and do not capture any signal independent of and beyond
that observed between rs1205 and CRP levels, adjusted for
sex and age. Therefore, we focused on the SNP rs1205, which
represents the allele that captures the strongest effects of the
gene on CRP levels. The SNP rs1800947 is also strongly
associated with CRP levels, but the MAF of rs1800947 is so
low that it is difficult to analyze this SNP fully in the context
of interaction with BMI.
The association for BMI and CRP levels is shown in Figure 1.
For both men and women there is a clear relationship between
increasing BMI and CRP levels for individuals with a G allele.
This relationship is of the magnitude of 5.7% (95% CI: 4.8; 6.6)
for an increase of one BMI unit in both sexes but is different for
the AA homozygote. In Table 4 , the interaction of BMI, waist
circumference and fat mass percent with genotypes of rs1205
on CRP levels is shown by genotype-specific b coefficients for
the association (representing effect of one unit change) and test
for equivalence. Results for men and women were tested
separately. There is a statistically significant interaction between
BMI and r1205 (P¼0.045) and also between waist circumfer-
ence and rs1205 in men (P¼0.014). Although the direction of
the effect for the G allele is the same in women the interaction
does not reach significance. However, this is not the case for fat
mass percent in either sex. BMI and waist circumference are
highly correlated factors (r¼0.85), though BMI and fat mass
percent are only moderately correlated (r¼0.32).
Discussion
Measuring of inflammatory markers has been used to try to
improve the prediction of common diseases. CRP is one such
inflammatory marker that has been associated with common
disease including coronary heart disease and diabetes and
therefore it is important to know what factors can influence
CRP levels. The results reported here are consistent with
Table 3 CRP levels according to rs1205 genotypes
CRP mg l1 (95% CI)a P-value
Men rs1205
AA (n¼77) 1.33 (1.11, 1.60)
AG (n¼ 411) 1.69 (1.54, 1.80) 0.0313b
GG (n¼421) 1.89 (1.75, 2.04) 0.0007
Women rs1205
AA (n¼119) 1.54 (1.33, 1.80)
AG (n¼ 562) 1.86 (1.74, 2.00) 0.0261
GG (n¼554) 1.94 (1.80, 2.08) 0.0077
Adjusted for age and excluding CRP410 mg l1. aGeometric means.
bBetween AG and GG, P¼0.0256.
AA
AG
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Figure 1 The association of body mass index (BMI) with log-CRP in rs1205
genotypes. The increase in C-reactive protein (CRP) levels with BMI is different for
the AA genotype than for the GA and GG genotypes in both men (left) and
women (right). The marks (dot, triangle and cross) represent mean log-CRP values
by genotypes around BMI values of 20, 25, 30 and 35 using bins of width 5.
Table 4 The interaction of anthropometric measurements with genotypes of rs1205 on circulating CRP levels shown by genotype-specific b coefficients for the
association, representing effect of one unit change
rs1205 genotype BMI N¼ 904 WC N¼904 F% N¼754
Men b coefficient s.e. b coefficient s.e. b coefficient s.e.
AA 0.003 0.022 0.006 0.008 0.030 0.018
AG 0.049 0.011 0.015 0.004 0.021 0.007
GG 0.060 0.011 0.020 0.004 0.032 0.007
P for interactionfor 0.045 0.014 0.563
Women BMI N¼1226 WC N¼ 1226 F% N¼923
AA 0.031 0.017 0.012 0.006 0.025 0.017
AG 0.065 0.007 0.017 0.003 0.028 0.007
GG 0.048 0.007 0.015 0.003 0.050 0.007
P for interactionfor 0.088 0.780 0.054
Abbreviations: BMI, body mass index; F%, fat mass %; WC, waist circumference.
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many studies where polymorphisms in the CRP gene are
associated with CRP levels. In addition, the results presented
here confirm the effect of measures of adipose tissue on
circulating CRP levels found in other studies.12,16 The novel
finding in this study is the interaction of adiposity with CRP
genotypes to influence CRP levels where the relationship
of increasing CRP with adiposity is carried by selected
genotypes.
Total body fat has been shown to be a predictor of
circulating CRP levels but it is also important to understand
the possible influence of fat distribution in the production of
low-grade inflammatory markers. Visceral fat has been
shown to be important as a promoter of moderately
increased CRP levels in both sexes.29–31 BMI, fat mass percent
and waist circumference, which is thought to be a surrogate
for visceral fat, are shown here to be positively associated
with CRP levels, in both men and women. BMI and waist
circumference have a different effect on CRP levels in
individuals with the AA genotype of the rs1205 SNP than
carriers of the G allele. The difference is more pronounced in
men than women. The association of the adiposity measure-
ments with CRP levels is carried by the GG and GA
genotypes and the effect is of the same magnitude for
both sexes. The size of the effect is larger for BMI than
for waist circumference. This difference in effect between
the AA genotype and G carriers was not seen for the fat
mass percent and could thus suggest that fat localization
might be involved in CRP production as shown in other
studies.15,29–31
Considerable work has been done in determining the
mechanism of expression of the CRP gene. The regulatory
effect of the adipocyte-produced IL-6 on the transcription of
the CRP gene has been carefully studied11–13 and binding
sites for liver transcription factors have been identified in the
CRP promoter.32 Carlson et al.20 made a number of promoter
constructs of the CRP gene demonstrating an effect of IL-6
on CRP production by a variation in the promoter region.
Another possibility for regulation is through the stability of
the mRNA and could be important because of the known
short half-life of CRP mRNA.33 Brull et al.34 suggested that
the SNP rs1130864 in the 30UTR is related to CRP mRNA
levels, an effect that was not influenced by cytokines. In this
study, the interaction of adiposity is shown specifically with
genotypes of the rs1205 SNP, which is in the 30 flanking
region of the gene. This effect could possibly be explained in
that obesity stimulates through the G allele a more stable
mRNA. Because of the strong LD over the CRP gene, both
mechanisms could explain the consistently lower CRP levels
associated with the rs1205 AA genotype,4,35 which has weak
if any association with CRP levels and increasing obesity.
Many studies have put emphasis on determining haplo-
type effect on disease. Risk haplotypes in the CRP gene have
been reported for CVD22 and diabetes8,36 and CRP level has
been shown to be an independent risk factor for both these
common diseases although not over and above other known
risk factors.3 In our data, these haplotypes did not add to the
effect on CRP levels beyond the effect of the single SNP,
rs1205. This is most likely reflected in the fact that there is
extremely strong LD over and upstream of the CRP gene as
identified with our panel of SNPs and has been discussed in a
recent review paper.6 This calls out for further genetic studies
using more detailed fat measures as well as more detailed
measures of proinflammatory molecules produced in fat
tissue, for example, IL-6, which are necessary to determine
whether the genetic interaction is mediated through these
types of stimulants of CRP production.
The AA genotype of the rs1205 SNP has consistently been
shown to be associated with low CRP4,35 and has also been
found to be associated with lower cardiovascular mortality.4
Genetic effects in common diseases are generally small26,36
but gene/environment interaction could be important in
modulating risk for common diseases. Such a gene/environ-
ment interaction is reported here where the effect of BMI
and waist circumference on the levels of circulating CRP may
be mediated by an adipose-tissue-related factor acting in an
allele-specific way through the CRP gene.
Acknowledgements
This study was funded by National Institutes of Health
contract N01-AG-12100, the National Institute on Aging
Intramural Research Program, Hjartavernd (the Icelandic Heart
Association) and the Althingi (the Icelandic Parliament).
References
1 Finch CE, Morgan T. Systemic inflammation, infection, ApoE
alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res
2007; 4: 185–189.
2 Zaciragic A, Lepara O, Valjevac A, Arslanagic S, Fajkic A,
Hadzovic-Dzuvo A et al. Elevated serum C-reactive protein
concentration in Bosnian patients with probable Alzheimer’s
disease. J Alzheimers Dis 2007; 12: 151–156.
3 Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G,
Rumley A et al. C-reactive protein and other circulating markers
of inflammation in the prediction of coronary heart disease.
N Engl J Med 2004; 350: 1387–1397.
4 Lange LA, Carlsson CS, Hindorff LA, Lange EM, Walston J, Durda
JP et al. Association of polymorphisms in the CRP gene with
circulating C-reactive protein levels and cardiovascular events.
JAMA 2006; 296: 2703–2711.
5 Kolz M, Koenig W, Mu¨ller M, Andreani M, Greven S, Illig T et al.
DNA variants, plasma levels and variability of C-reactive protein
in myocardial infarction survivors: results from the AIRGENE
study. Eur Heart J 2008; 29: 1250–1258.
6 Hage FG, Szalai AJ. C-reactive protein gene polymorphisms,
C-reactive protein blood levels, and cardiovascular disease risk.
J Am Coll Cardiol 2007; 50: 1115–1122.
7 Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL,
Buckley BM et al. C-reactive protein and prediction of coronary
heart disease and global vascular events in the Prospective Study
of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007;
115: 981–999.
Adiposity interaction with CRP gene: AGES-Reykjavik
G Eiriksdottir et al
271
International Journal of Obesity
8 Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ,
Bootsma AH et al. Genetic variation, C-reactive protein levels,
and incidence of diabetes. Diabetes 2007; 56: 872–878.
9 Freeman DJ, Nome J, Caslake MJ, Gaw A, Ford I, Lowe GD et al.
C-reactive protein is an independent predictor of risk for the
development of diabetes in the West of Scotland Coronary
Prevention Study. Diabetes 2002; 51: 1596–1600.
10 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive
protein, interleukin 6, and risk of developing type 2 diabetes
mellitus. JAMA 2001; 286: 327–334.
11 Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D. Do post-
transcriptional mechanisms participate in induction of C-reactive
protein and serum amyloid A by IL-6 and IL-1? Ann NY Acad Sci
1995; 762: 102–107.
12 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive
protein in healthy subjects: associations with obesity, insulin
resistance, and endothelial dysfunction: a potential role for
cytokines originating from adipose tissue? Arterioscler Thromb
Vasc Biol 1999; 19: 972–978.
13 Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H
et al. Recent advances in the relationship between obesity,
inflammation, and insulin resistance. Eur Cytokine Netw 2006;
17: 4–12.
14 Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A
et al. The inflammatory C-reactive protein is increased in both
liver and adipose tissue in severely obese patients independently
from metabolic syndrome, type 2 diabetes, and NASH. Am J
Gastroenterol 2006; 101: 1824–1833.
15 Memoli B, Procino A, Calabro` P, Esposito P, Grandaliano G,
Pertosa G et al. Inflammation may modulate IL-6 and C-reactive
protein gene expression in the adipose tissue: the role of IL-6 cell
membrane receptor. Am J Physiol Endocrinol Metab 2007; 293:
E1030–E1035.
16 Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive
protein to body fat distribution and features of the metabolic
syndrome in Europeans and South Asians. Int J Obes Relat Metab
Disord 2001; 9: 1327–1331.
17 Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.
Elevated C-reactive protein levels in overweight and obese adults.
JAMA 1999; 282: 2131–2135.
18 Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous
adipose tissues of obese subjects release interleukin-6: depot
difference and regulation by glucocorticoid. J Clin Endocrinol
Metab 1998; 83: 847–850.
19 Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE et al. Loci
related to metabolic-syndrome pathways including LEPR,
HNF1A, IL6R, and GCKR associate with plasma C-reactive
protein: the Women’s Genome Health Study. Am J Hum Genet
2008; 82: 1185–1192.
20 Carlson CS, Lee PK, Tracy RP, Stephen M, Schwartz SM, Liu K et al.
Polymorphisms within the C-reactive protein (CRP) promoter
region are associated with plasma CRP levels. Am J Hum Genet
2005; 77: 64–77.
21 Crawford DC, Qin X, Smith JD, Shephard C, Wong M, Witrak L
et al. Genetic variation is associated with C-reactive protein levels
in the Third National Health and Nutrition Examination Survey.
Circulation 2006; 114: 2458–2465.
22 Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney Jr JF
et al. Contribution of clinical correlates and 13 C-reactive protein
gene polymorphisms to interindividual variability in serum
C-reactive protein level. Circulation 2006; 113: 1415–1423.
23 Balistreri CR, Vasto S, Listı` F, Grimaldi MP, Lio D, Colonna-
Romano G et al. Association between+1059G/C CRP polymorph-
ism and acute myocardial infarction in a cohort of patients from
Sicily: a pilot study. Ann NY Acad Sci 2006; 1067: 276–281.
24 Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein
(CRP) gene polymorphisms, CRP levels, and risk of incident
coronary heart disease in two nested case–control studies. PLoS
ONE 2008; 3: e1395.
25 Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH et al.
Association study of CRP gene polymorphisms with serum CRP
level and cardiovascular risk in the NHLBI Family Heart Study.
Am J Physiol Heart Circ Physiol 2006; 291: H2752–H2757.
26 Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A,
Stricker BH et al. C-reactive protein and risk of heart failure. The
Rotterdam Study. Am Heart J 2006; 152: 514–520.
27 Jo´nsdo´ttir LS, Sigfusson N, Sigvaldason H, Thorgeirsson G.
Incidence and prevalence of recognised and unrecognised
myocardial infarction in women. The Reykjavik Study. Eur Heart
J 1998; 19: 1011–1018.
28 Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV,
Sigurdsson G et al. Age, Gene/Environment Susceptibility-
Reykjavik Study: multidisciplinary applied phenomics. Am J
Epidemiol 2007; 165: 1076–1087.
29 Lemieux I, Pascot A, Prud’homme D, Alme´ras N, Bogaty P,
Nadeau A et al. Elevated C-reactive protein another component of
the atherothrombotic profile of abdominal obesity . Arterioscler
Thromb Vasc Biol 2001; 21: 961–967.
30 Piche´ ME, Lapointe A, Weisnagel SJ, Corneau L, Nadeau A,
Bergeron J et al. Regional body fat distribution and metabolic
profile in postmenopausal women. Metabolism 2008; 57:
1101–1107.
31 Piche´ ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A,
Bergeron J. Relation of high-sensitivity C-reactive protein,
interleukin-6, tumor necrosis factor-alpha, and fibrinogen to
abdominal adipose tissue, blood pressure, and cholesterol and
triglyceride levels in healthy postmenopausal women. Am J
Cardiol 2005; 96: 92–97.
32 Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G.
Synergistic trans-activation of the human C-reactive protein
promoter by transcription factor HNF-1 binding at two distinct
sites. EMBO J 1990; 9: 4467–4475.
33 Lozanski G, Jiang SL, Samols D, Kushner I. C-reactive protein and
serum amyloid A mRNA stability following induction by
cytokines. Cytokine 1996; 8: 534–540.
34 Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A
et al. Human CRP gene polymorphism influences CRP levels:
implications for the prediction and pathogenesis of coronary
heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063–2069.
35 Danik JS, Ridker PM. Genetic determinants of C-reactive protein.
Curr Atheroscler Rep 2007; 9: 195–203.
36 Zee RY, Germer S, Thomas A, Raji A, Rhees B, Ridker PM et al.
C-reactive protein gene variation and type 2 diabetes mellitus: a
case–control study. Atherosclerosis 2008; 197: 931–936.
Adiposity interaction with CRP gene: AGES-Reykjavik
G Eiriksdottir et al
272
International Journal of Obesity
